(Q51032432)

27 March 2018

title

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). (English)

1 reference

27 March 2018

0 references

1 reference

M Pinget

1

1 reference

27 March 2018

R Goldenberg

2

1 reference

27 March 2018

E Niemoeller

3

1 reference

27 March 2018

I Muehlen-Bartmer

4

1 reference

27 March 2018

H Guo

5

1 reference

27 March 2018

R Aronson

6

1 reference

27 March 2018

publication date

26 May 2013

1 reference

27 March 2018

Diabetes, Obesity and Metabolism

published in

1 reference

27 March 2018

volume

15

1 reference

27 March 2018

issue

11

1 reference

27 March 2018

page(s)

1000-1007

1 reference

27 March 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

cites work

1 reference

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

21 January 2018

1 reference

Lixisenatide for type 2 diabetes mellitus

21 January 2018

1 reference

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

21 January 2018

1 reference

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

21 January 2018

1 reference

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

21 January 2018

1 reference

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12121

1 reference

27 March 2018

PubMed ID

23627775

1 reference

27 March 2018